Abstract:Rationale: Approximately 80% of patients with non-familial pulmonary arterial hypertension (PAH) lack identifiable pathogenic genetic variants. While most genetic studies of PAH have focused on predicted loss-of-function variants, recent approaches have identified ultra-rare missense variants associated with the disease. FOXF1 encodes a highly conserved transcription factor, essential for angiogenesis and vasculogenesis in human and mouse lungs. Objectives: We identified a rare FOXF1 missense coding variant in two unrelated probands with PAH. FOXF1 is an evolutionarily conserved transcription factor required for lung vascular development and vascular integrity. Our aims were to determine the frequency of FOXF1 variants in larger PAH cohorts compared to the general population, study FOXF1 expression in explanted lung tissue from PAH patients versus control (failed-donor) lungs, and define potential downstream targets linked to PAH development. Methods: Three independent, international, multicenter cohorts were analyzed to evaluate the frequency of FOXF1 rare variants. Various composite prediction models assessed the deleteriousness of individual variants. Bulk RNA sequencing datasets from human explanted lung tissues were compared to failed-donor controls to determine FOXF1 expression. Bioinformatic tools identified putative FOXF1 binding targets, which were orthogonally validated using mouse ChIP-seq datasets. Measurements and Main Results: Seven novel or ultra-rare missense coding variants were identified across three patient cohorts in different regions of the FOXF1 gene, including the DNA binding domain. FOXF1 expression was dysregulated in PAH lungs, correlating with disease severity. Histological analysis showed heterogeneous FOXF1 expression, with the lowest levels in phenotypically abnormal endothelial cells within complex vascular lesions in PAH samples. A hybrid bioinformatic approach identified FOXF1 downstream targets potentially involved in PAH pathogenesis, including BMPR2. Conclusions: Large genomic and transcriptomic datasets suggest that decreased FOXF1 expression or predicted dysfunction is associated with PAH.

Molecular genetic framework underlying pulmonary arterial hypertension

Genes in pediatric pulmonary arterial hypertension and the most promising BMPR2 gene therapy

Epigenetic Regulation of Pulmonary Arterial Hypertension

Identification of a Novel Mutation in the BMPR2 Gene in a Pulmonary Arterial Hypertension Patient Using Next‐generation Sequencing

Identification of rare sequence variation underlying heritable pulmonary arterial hypertension

[Genetic, cellular and molecular mechanisms of pulmonary arterial hypertension]

Genetic background of pulmonary (vascular) diseases - how much is written in the codes?

New Mutations and Pathogenesis of Pulmonary Hypertension: Progress and Puzzles in Disease Pathogenesis

Genetics and precision genomics approaches to pulmonary hypertension

Exploring the pathogenesis of pulmonary vascular disease

Unraveling the epigenetic landscape of pulmonary arterial hypertension: implications for personalized medicine development

Bone morphogenetic protein signalling in pulmonary arterial hypertension: revisiting the BMPRII connection

The features of rare pathogenic BMPR2 variants in pulmonary arterial hypertension: Comparison between patients and reference population

Causal associations between telomere length and pulmonary arterial hypertension: A two-sample Mendelian randomization study

Unraveling the genetic landscape of pulmonary arterial hypertension in Indian patients: A transcriptome study

BMPR2 Mutation and Metabolic Reprogramming in Pulmonary Arterial Hypertension

A review of BMP and Wnt signaling pathway in the pathogenesis of pulmonary arterial hypertension

SOX17 Loss-of-Function Mutation Underlying Familial Pulmonary Arterial Hypertension.

Role of Forkhead box F1 in the Pathobiology of Pulmonary Arterial Hypertension

Mechanisms of lung endothelial cell injury and survival in pulmonary arterial hypertension

Application of transcriptomics and proteomics in pulmonary arterial hypertension